Navigation Links
Eight-Year Melanoma Remission is Among Early Cancer Treatment Results

NASHVILLE, Tenn., July 14 /PRNewswire/ -- A newly available treatment already has benefited several individuals with aggressive malignancies. Offered through NeoPlas Innovation, this regimen has arrested or eradicated tumors in more than 80% of initial patients. Director of Research Dr. Stephen Cantrell emphasized that human testing is in its early stages, but added, "These results have surprised us. This is far beyond what currently available standard treatments achieve."

Melanoma, a deadly form of malignant skin cancer, is among the diseases targeted to date. The first person treated with the investigative protocol had stage 4 melanoma and a life expectancy of eight weeks. He experienced a complete response and remains disease-free eight years later. While not all results have been this dramatic, each NeoPlas melanoma patient has had results significantly better than those with standard therapy. Eradication of tumors or long-term stability has occurred in most patients; others have seen a substantial slowing of progression.

The new protocol incorporates a unique combination of FDA-approved drugs used by millions of people for other applications. When administered alone, these drugs show some benefit against cancer, but not enough to make a difference for most patients. The combination of the medicines, however, allows lower, more tolerable dosages and provides effectiveness not seen in previous, single-drug studies.

The NeoPlas treatment disables certain abnormal cellular processes many of the aggressive malignancies share. Based on experience and relevant lab research to date, staff members expect the best results for: melanoma, pancreatic cancer, colon cancer, renal (kidney) cancer, mesothelioma, and a group of sarcomas, including osteosarcoma, chondrosarcoma and malignant fibrous histiocytoma. The regimen is not expected to have significant benefit against brain tumors.

The most notable side effect is fatigue. Most patients never experience side effects commonly affiliated with chemotherapy or radiation (nausea, vomiting, hair loss, bone marrow suppression or immune system suppression). An experienced physician prescribes and monitors all treatment and maintains close communication with the patient's established oncologist. Having received previous cancer treatments does not make a patient ineligible for the outpatient NeoPlas regimen.

A Web site,, provides answers to common questions and an interactive screening tool. Individuals can reach NeoPlas at 615-371-8100 or by e-mailing

SOURCE NeoPlas Innovation
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Long-Term Pegylated Interferon Alfa-2b Therapy in Stage III Melanoma Demonstrated Significant and Sustained Impact on Relapse-Free Survival
2. Journal of Clinical Oncology Publishes Leukine(R) Study Demonstrating Positive Survival Outcomes in Patients with High-Risk Melanoma
3. Genta Updates Progress of its Phase 3 Trial of Genasense(R) in Patients with Advanced Melanoma
4. Patients Own Infection-Fighting T Cells Put Late-Stage Melanoma Into Long-Term Remission - Without Chemotherapy or Radiation
5. CuraGen Announces Expansion of CR011-vcMMAE Phase II Trial in Melanoma
6. Study Supports Possible Use of Leukine(R) as a Potential Adjuvant Therapy for High-Risk Melanoma Patients
7. Delcath Expands Phase III Trial for Metastatic Melanoma to Include St. Lukes Cancer Center
8. Anti-TGF-Beta Antisense AP 12009 Shows Very Good Safety and Tolerability in Systemic Treatment of Pancreatic Carcinoma, Malignant Melanoma and Colorectal Carcinoma
9. CuraGen Announces Data From Ongoing Phase I/II Trial Showing Clinical Activity of CR011-vcMMAE in Metastatic Melanoma
10. Ipilimumab Plus Chemotherapy is Associated with Prolonged Survival and Increased Disease Control Rates in Patients with Advanced Melanoma
11. BioVex Reports Positive Phase II Clinical Trial Results of OncoVEX GM-CSF in Metastatic Melanoma at the 2008 American Society of Clinical Oncology Meeting
Post Your Comments:
(Date:6/23/2016)... 23, 2016  MedSource announced today that it ... software solution of choice.  This latest decision demonstrates ... to their clients by offering a state-of-the-art electronic ... establishes nowEDC as the EDC platform of choice ... clients.  "nowEDC has long been a preferred EDC ...
(Date:6/23/2016)... Any dentist who has made an implant supported ... Many of them do not even offer this as a ... laboratory costs involved. And those who ARE able to offer ... high cost that the majority of today,s patients would not ... Zadeh , founder of Dental Evolutions Inc. and inventor of ...
(Date:6/23/2016)... , June 23, 2016  In a startling report released today, ... their residents by lacking a comprehensive, proven plan to eliminate prescription ... definitive ranking of how states are tackling the worst drug crisis ... four states – Kentucky , New ... Vermont . Of the 28 failing states, three – ...
Breaking Medicine Technology:
(Date:6/24/2016)... ... ... was in a crisis. Her son James, eight, was out of control. Prone to extreme ... “When something upset him, he couldn’t control his emotions,” remembers Marcy. “If there was ... other children and say he was going to kill them. If we were driving ...
(Date:6/24/2016)... Francisco, CA (PRWEB) , ... June 24, 2016 ... ... CitiDent, is now offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive ... self-ligating Damon brackets , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation ...
(Date:6/24/2016)... Plano, TX (PRWEB) , ... June 24, 2016 , ... ... taking part in Genome magazine’s Code Talker Award, an essay contest in which patients ... for an award to be presented at the 2016 National Society of Genetic Counselors ...
(Date:6/24/2016)... Vegas, Nevada (PRWEB) , ... June 24, 2016 ... ... Las Vegas client, The Grove Investment Group (TGIG), has initiated cultivation and processing ... Grove, in Las Vegas and Pahrump, Nevada. , Puradigm is the manufacturer of ...
(Date:6/24/2016)... ... 2016 , ... Venture Construction Group (VCG) sponsors Luke’s Wings ... at the Woodmont Country Club at 1201 Rockville Pike, Rockville, Maryland, 20852. The ... members that have been wounded in battle and their families. Venture Construction Group is ...
Breaking Medicine News(10 mins):